Drew Hoffman
dhoffman@echo.globaland/or marketing@echo.global
405.279.6664
April 13, 2023
Wheeler Bio, a CDMO specializing in therapeutic antibodies, has closed its Series A funding round, co-led by Charles River Laboratories and Echo. The firm's Portable CMC is an open-source middleware that enhances the gene-to-IND supply chain, delivering speed, efficiency, predictability, and freedom to operate. The firm intends to complete a 500L scale CGMP cell banking and drug substance manufacturing facility in Oklahoma City, with the first batches of production set to commence in Q3 2023. The new facility will utilize integrated tools and technologies like Solentim, Ambr Microbioreactors, and DynaDrive Single-Use Bioreactors.
Read More
April 5, 2023
Deka Biosciences has announced the dosing of the first subject in a Phase 1 clinical trial of DK210 (EGFR), a novel cytokine therapy for cancer and inflammatory diseases. The trial aims to evaluate the safety, potential efficacy, and biomarker responses of the therapy in patients with advanced solid cancer(s) expressing epidermal growth factor receptors. DK210 (EGFR) is the first of several DiakinesTM developed by Deka, which involves coupling two cytokines onto a single targeting system for enhanced precision and efficacy. The self-administered treatment is expected to provide patients with greater comfort and convenience.
Read More
January 30, 2023
Deka Biosciences ("Deka"), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for DK210 (EGFR) and concluded that Deka may proceed with a Phase 1 clinical trial in the United States.
Read More
December 12, 2022
Is Hollywood moving to the prairie? Omar Villafranca takes a look at how Oklahoma state incentives are bringing motion-picture production to the state.
Read More
November 3, 2022
Contract Development and Manufacturing Organization (CDMO) Wheeler Bio and CRB – a leading global provider of sustainable engineering, architectural, construction and consulting services to the life sciences industry – today announced the start of construction on a GMP drug substance facility that will support innovators seeking agile, small batch manufacturing services for their clinical trial materials (CTM).
Read More